Lite Strategy (LITS) Other Working Capital Changes (2018 - 2024)
Lite Strategy (LITS) posted quarterly Other Working Capital Changes of -$12.6 million for Q2 2024, up 57.66% year-over-year from -$8.0 million in Q3 2023, and down 3386.39% quarter-over-quarter from -$360000.0 in Q1 2024.
Lite Strategy (LITS) Other Working Capital Changes (2018 - 2024) Analysis & Trends
Lite Strategy's Other Working Capital Changes history runs 7 years deep, the most recent figure standing at -$12.6 million for Q2 2024.
- In Q2 2024, Other Working Capital Changes rose 57.66% year-over-year to -$12.6 million; the TTM figure through Mar 2025 stood at -$12.6 million (up 59.13% YoY), while the FY2024 annual figure was -$13.6 million, up 55.49% from the prior year.
- Other Working Capital Changes for Q2 2024 stood at -$12.6 million, down from -$360000.0 in the prior quarter.
- The five-year high for Other Working Capital Changes was $2.9 million in Q2 2023, with the low at -$4.1 million in Q1 2024.
- The 5-year median for Other Working Capital Changes is -$183500.0 (2025), against an average of -$267000.0.
- The sharpest annual moves came in 2020 and 2023: Other Working Capital Changes jumped 12249.15% in 2020, then sank 21027.69% in 2023.
- Lite Strategy's Other Working Capital Changes stood at -$2.4 million in 2020, then soared by 30.82% to -$1.7 million in 2021, then plunged by 1547.53% to -$27.7 million in 2022, then soared by 331.67% to $64.2 million in 2023, then slumped by 119.56% to -$12.6 million in 2024.
- Business Quant data shows LITS's Other Working Capital Changes at -$12.6 million in Q2 2024, -$360000.0 in Q1 2024, and $64.2 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Lite Strategy | 33.69 Mn | 26.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -12.55 Mn |
| Jun 30, 2024 | -12.55 Mn |
| Jun 30, 2024 | -12.55 Mn |
| Mar 31, 2024 | -360,000.00 |
| Mar 31, 2024 | -360,000.00 |
| Mar 31, 2024 | -360,000.00 |
| Dec 31, 2023 | 64.16 Mn |
| Dec 31, 2023 | 64.16 Mn |
| Dec 31, 2023 | 64.16 Mn |
| Sep 30, 2023 | -64.86 Mn |
| Sep 30, 2023 | -64.86 Mn |
| Sep 30, 2023 | -64.86 Mn |
| Jun 30, 2023 | -29.65 Mn |
| Jun 30, 2023 | -29.65 Mn |
| Jun 30, 2023 | -29.65 Mn |
| Mar 31, 2023 | 27.07 Mn |
| Mar 31, 2023 | 27.07 Mn |
| Mar 31, 2023 | 27.07 Mn |
| Dec 31, 2022 | -27.70 Mn |
| Dec 31, 2022 | -27.70 Mn |